Share

December 11, 2018; 91 (24) Article

Body mass index, but not vitamin D status, is associated with brain volume change in MS

Ellen M. Mowry, Christina J. Azevedo, Charles E. McCulloch, Darin T. Okuda, Robin R. Lincoln, Emmanuelle Waubant, Stephen L. Hauser, Daniel Pelletier
First published November 14, 2018, DOI: https://doi.org/10.1212/WNL.0000000000006644
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
263

Share

Article Information

vol. 91 no. 24 e2256-e2264
DOI: 
https://doi.org/10.1212/WNL.0000000000006644
PubMed: 
30429274
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received April 14, 2018
  • Accepted in final form August 27, 2018
  • First Published November 14, 2018.

Article Versions

Copyright & Usage: 
© 2018 American Academy of Neurology

Author Disclosures

    1. Ellen M. Mowry, MD, MCR,
    2. Christina J. Azevedo, MD, MPH,
    3. Charles E. McCulloch, PhD,
    4. Darin T. Okuda, MD,
    5. Robin R. Lincoln, BS,
    6. Emmanuelle Waubant, MD, PhD,
    7. Stephen L. Hauser, MD and
    8. Daniel Pelletier, MD
  1. Ellen M. Mowry, MD, MCR,
    2. Scientific Advisory Boards:

    1. DSMB for liothyronine study (non-profit)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial board, Frontiers in Neuroepidemiomology, 2017- present

    Patents:

    1. NONE

    Publishing Royalties:

    1. UptoDate chapter editor (Pathogenesis and epidemiology of multiple sclerosis)

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1)Free glatiramer acetate for a clinical trial from Teva Neuroscience. (2)Research funding paid to my institution from Biogen Idec and Genzyme (for investigator-initiated studies). (3) Site PI of two trials sponsored by Sun Pharma and Biogen

    Research Support, Government Entities:

    1. (1)Department of Defense

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1. National Multiple Sclerosis Society RG4407A22. 2. National Multiple Sclerosis Society JF2164A7 3. Patient- Centered Outcomes Research Institute (PCORI)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Christina J. Azevedo, MD, MPH,
    3. Scientific Advisory Boards:

    1. In the past two years, I have received honoraria for serving on scientific advisory boards for: (1) Genentech (2) Guerbet, L.L.C. (3) Biogen-Idec (4) Genzyme

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. I am supported by a 3-year Institutional Career Development Award through the Southern California Clinical and Translational Science Institute (Grant # UL1TR001855 from the National Center for Advancing Translational Science) My role is an Institutional Scholar.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Charles E. McCulloch, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH, KL2 RR024130, Biostatistics mentor, 2010-2012

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Darin T. Okuda, MD,
    5. Scientific Advisory Boards:

    1. DSMB Chair (Osmotica)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1. Acorda, travel and speaker fees 2. Genzyme, travel and speaker fees 3. Teva, travel and speaker fees

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1). Celgene (2). Bayer (3). EMD Serono (4). Genzyme (5). Novartis

    Speakers' Bureaus:

    1. (1). Acorda Therapeutics (2). Genzyme (3). TEVA

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Robin R. Lincoln, BS,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Emmanuelle Waubant, MD, PhD,
    7. Scientific Advisory Boards:

    1. I volunteer on a Novartis advisory board (pharmaceutical company)for a clinical trial

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. AAN has covered my travel and provided an honorarium in 2018 for my talk in Frontiers in Neurosciences

    Editorial Boards:

    1. -Section editor for Annals of Clinical and Translational Neurology since 2017 -Co-chief Editor for MSARD since 2016

    Patents:

    1. NONE

    Publishing Royalties:

    1. Demyelinating disorders of the central nervous system in childhood. Cambridge University. 2011 Pediatric MS and related disorders. 2017

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. I am site PI for trials of ocrelizumab in PPMS (Roche, company), and fingolimod in pediatric MS (Novartis, company)

    Research Support, Government Entities:

    1. I am co-PI for a trial sponsored by PCORI

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. I am supported by the National MS Society RG4861A3/1 (PI Waubant), and the Race to Erase MS (medical director)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Stephen L. Hauser, MD and
    8. Scientific Advisory Boards:

    1. Dr. Stephen L. Hauser serves on the scientific advisory boards for Bionure,Annexon,Alector, Symbiotix, and Molecular Stethoscope. He serves on the board of trustees for Neurona.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. (1) Harrison's Principles of Internal Medicine, McGraw-Hill Publishers, 1994-present

    Employment, Commercial Entity:

    1. (1)University of California, San Francisco, Professor of Neurology, Director of the Weill Institute for Neurosciences.

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH Funding, Grant # R01 NS092835 NIH Funding, Grant # R01 NS026799 NIH Funding, Grant # R01 NS099240

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Multiple Sclerosis Society (NMSS), Grant # RR 2005-A-13 (G-1510-06785); RG-1611-26299 Conrad Hilton Foundation, 16850

    Stock/Stock Options/Board of Directors Compensation:

    1. (1)Bionure, Dr. Hauser received stock options from Bionure, all of which were transferred to his institution (UCSF) (2) Annexon, Dr. Hauser received stock options from Annexon, all of which were transferred to his institution (UCSF) (3) Symbiotix, Dr. Hauser received stock options from Symbiotix, all of which were transferred to his institution (UCSF)

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Daniel Pelletier, MD
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr. Pelletier received consulting fees from Biogen, Sanofi-Genzyme, Novartis, Hoffmann LaRoche, and Actelion.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (E.M.M.), Johns Hopkins University, Baltimore, MD; Department of Neurology (C.A., D.P.), University of Southern California, Los Angeles; Department of Epidemiology and Biostatistics (C.E.M.) and MS Center (R.R.L., E.W., S.L.H.), Department of Neurology, University of California, San Francisco; and Department of Neurology (D.T.O.), University of Texas Southwestern, Dallas.
  1. Correspondence
    Dr. Mowry emowry1{at}jhmi.edu
View Full Text

Article usage

Article usage: November 2018 to March 2021

AbstractFullPdfSource
Nov 2018322034Highwire
Dec 2018135113265Highwire
Jan 20193173327Highwire
Feb 20192011915Highwire
Mar 20191621212Highwire
Apr 2019112137Highwire
May 201967159Highwire
Jun 201964106Highwire
Jul 2019731415Highwire
Aug 20196388Highwire
Sep 20198088Highwire
Oct 2019521111Highwire
Nov 201997410Highwire
Dec 20196599Highwire
Jan 20208555Highwire
Feb 202061310Highwire
Mar 20206222Highwire
Apr 20207111Highwire
May 20207800Highwire
Jun 20204633Highwire
Jul 20205510Highwire
Aug 20203521Highwire
Sep 20205852Highwire
Oct 20203810Highwire
Nov 20204910Highwire
Dec 20203900Highwire
Jan 20214511Highwire
Feb 20213611Highwire
Mar 20213611Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me